Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

NCT03720470 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

838

Enrollment

INDUSTRY

Sponsor class

Conditions

Dermatitis
Dermatitis, Atopic
Eczema
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases

Interventions

DRUG: PF-04965842 100 mg
DRUG: PF-04965842 200 mg
DRUG: Dupilumab
DRUG: Oral Placebo
DRUG: Injectable Placebo

Sponsor

Pfizer